- •The Sclera
- •Preface
- •Contents
- •1.1 Introduction
- •1.2 Development of the Sclera
- •1.2.1.1 First Week
- •1.2.1.2 Second Week
- •1.2.1.3 Third Week
- •1.2.1.4 Fourth Week
- •1.2.1.5 Fifth Week
- •1.2.1.6 Sixth Week
- •1.2.1.7 Seventh Week
- •1.2.1.8 Ninth Week
- •1.2.1.9 Tenth Week
- •1.2.1.10 Thirteenth Week
- •1.2.1.11 Sixteenth Week
- •1.2.1.12 Twenty-Fourth Week
- •1.2.2.1 Collagens
- •1.2.2.2 Proteoglycans
- •1.2.2.3 Glycoproteins
- •1.3 Anatomy
- •1.3.1 Gross and Microscopic Anatomy
- •1.3.1.1 Scleral Foramina
- •Anterior Scleral Foramen
- •Posterior Scleral Foramen
- •1.3.1.2 Layers of the Sclera
- •Episclera
- •Scleral Stroma
- •Lamina Fusca
- •1.3.1.3 Blood Supply and Emissary Canals
- •Vascular Distribution
- •Circulatory Dynamics
- •1.3.1.4 Nerve Supply
- •1.3.2 Ultramicroscopic Anatomy
- •1.3.2.1 Sclera
- •1.3.2.2 Vessels
- •1.4 Biochemistry
- •1.5 Immunohistochemistry
- •1.6 Biomechanics
- •1.7 Molecular Structure
- •1.7.1 Collagen
- •1.7.2 Elastin
- •1.7.3 Proteoglycans
- •1.7.4 Glycoproteins
- •1.7.6 Fibroblast Growth Regulation
- •1.8 Summary
- •References
- •2.1 General Immune Response Considerations
- •2.1.1 Components of the Adaptive Immune Response
- •2.1.1.1 Lymphocytes
- •T Lymphocytes
- •B Lymphocytes
- •Third-Population Lymphocytes or Null Lymphocytes
- •2.1.1.2 Monocytes/Macrophages
- •Phagocytosis
- •Antigen-Presenting Cells
- •2.1.1.3 Polymorphonuclear Granulocytes
- •Neutrophils
- •Eosinophils
- •Basophils/Mast Cells
- •2.1.1.4 Platelets
- •2.1.2 Immunoregulation
- •2.1.2.1 Major Histocompatibility Complex
- •2.1.2.2 Humoral Mechanisms: Antibodies
- •2.1.2.3 Cellular Mechanisms
- •2.1.2.4 Summary
- •2.1.3 Abnormalities of the Immune Response
- •2.1.3.1 Hypersensitivity Reactions
- •Type III Hypersensitivity Reactions
- •Systemic Immune Complex Disease
- •Local Immune Complex Disease (Arthus Reaction)
- •Type IV Hypersensitivity Reactions
- •2.1.3.2 Autoimmunity
- •Mechanisms of Autoimmunity
- •2.2 Connective Tissue and the Immune Response
- •2.2.1 Fibroblast Functions and the Immune Response
- •2.3 The Sclera and the Immune Response: Scleritis
- •2.3.1 Immune Characteristics of the Sclera
- •2.3.2 The Susceptible Host: Immunogenetics
- •2.3.3 Etiology
- •2.3.3.1 Exogenous Agents
- •Viruses
- •Mycobacteria
- •2.3.3.2 Endogenous Substances
- •Glycosaminoglycans
- •Collagen
- •2.3.4 Pathogenesis
- •2.4 Summary
- •References
- •3.1 Investigation of the Illness
- •3.1.1 Major Complaint and History of Present Illness
- •3.1.2 Past History
- •3.1.3 Family History
- •3.1.4 Past and Present Therapy History
- •3.1.5 Review of Systems
- •3.1.6 Systemic Examination
- •3.1.6.1 Head
- •3.1.6.2 Extremities
- •3.1.7 Ocular Examination
- •3.1.7.1 Episcleral and Scleral Examination
- •External Examination of the Eye in Daylight
- •Slit-Lamp Examination
- •Diffuse Illumination
- •Slit-Lamp Illumination
- •Red-Free Illumination
- •3.1.7.2 General Eye Examination
- •Visual Acuity
- •Pupils and Extraocular Muscles
- •Cornea
- •Anterior Uvea
- •Lens
- •Fundus
- •Intraocular Pressure
- •3.2 Diagnostic Tests
- •3.2.1 Blood Tests
- •3.2.1.1 Rheumatoid Factor
- •3.2.1.2 Anticyclic Citrullinated Peptide Antibodies
- •3.2.1.3 Antinuclear Antibodies
- •3.2.1.4 Antineutrophil Cytoplasmic Antibodies
- •3.2.1.5 Circulating Immune Complexes
- •Fluid-Phase Binding Assays
- •C1q-Binding Assay
- •Cell-Binding Assays
- •Raji Cell-Binding Assay
- •3.2.1.6 Complement
- •Quantitation Tests
- •Functional Tests
- •3.2.1.7 HLA Typing
- •3.2.1.8 Antibody Titers Against Infectious Organisms
- •3.2.1.9 Interferon-Gamma Release Assays (IGRAs)
- •3.2.2 Anterior Chamber Polymerase Chain Reaction Testing
- •3.2.3 Smears and Cultures
- •3.2.4 Skin Testing
- •3.2.5 Radiologic Studies
- •3.2.6.1 Anterior Segment Fluorescein Angiography Techniques
- •3.2.6.2 Normal Anterior Segment Fluorescein Angiography
- •Arterial Phase
- •Capillary Phase
- •Venous Phase
- •3.2.7 Anterior Segment Indocyanine Green Angiography
- •3.2.8 Other Imaging Studies
- •3.2.8.1 Ultrasonography
- •A-Scan Ultrasonography
- •B-Scan Ultrasonography
- •High-Frequency Ultrasound Biomicroscopy
- •3.2.8.2 Optical Coherence Tomography
- •3.2.8.3 Computer Tomography Scanning
- •3.2.8.4 Magnetic Resonance Imaging
- •3.3 Biopsy
- •3.3.1 Biopsy for Suspected Systemic Vasculitic Disease
- •3.4 Data Integration: Diagnosis
- •3.5 Therapeutic Plan
- •3.6 Summary
- •References
- •4.1 Episcleritis
- •4.1.1 Introduction
- •4.1.2 Patient Characteristics
- •4.1.3 Clinical Manifestations
- •4.1.4.1 Simple Episcleritis
- •4.1.4.2 Nodular Episcleritis
- •4.1.5 Associated Diseases
- •4.1.6 Precipitating Factors
- •4.2 Scleritis
- •4.2.1 Introduction
- •4.2.2 Patient Characteristics
- •4.2.3 Clinical Manifestations
- •4.2.4.1 Diffuse Anterior Scleritis
- •4.2.4.2 Nodular Anterior Scleritis
- •Differential Diagnosis
- •Paralimbic Scleromalacia
- •Senile Scleral Hyaline Plaques
- •4.2.4.5 Posterior Scleritis
- •Symptoms and Signs
- •Fundus Findings
- •Choroidal Folds
- •Subretinal Mass
- •Disk Edema and Macular Edema
- •Annular Ciliochoroidal Detachment and Serous Retinal Detachment
- •Associated Diseases
- •Complications
- •Ancillary Tests
- •Ultrasonography
- •Computerized Tomography (CT) Scanning
- •Fluorescein Angiography
- •Differential Diagnosis
- •Proptosis, Chemosis, Lid Swelling, and Limitation of Ocular Movements
- •Subretinal Mass
- •Choroidal Folds
- •Annular Ciliochoroidal Detachment and/or Serous Retinal Detachment
- •Disk and Macular Edema
- •4.2.5 Associated Diseases
- •4.2.6 Complications of Scleritis
- •4.2.6.1 Keratopathy
- •Peripheral Corneal Thinning
- •Stromal Keratitis
- •Peripheral Ulcerative Keratitis
- •4.2.6.2 Uveitis
- •4.2.6.3 Glaucoma
- •Angle-Closure Glaucoma
- •Open-Angle Glaucoma
- •Neovascular Glaucoma
- •4.2.6.4 Cataract
- •4.3 Summary
- •References
- •5: Pathology in Scleritis
- •5.1.3 Fibrinoid Necrosis
- •5.2.1 Pathology of Episcleritis
- •5.2.2 Pathology of Scleritis
- •5.2.2.1 Noninfectious Scleritis
- •Sclera
- •Cells
- •Extracellular Matrix
- •Vessels
- •Episclera
- •Conjunctiva
- •Iris, Ciliary Body, and Choroid
- •Cornea
- •Other Ocular Structures
- •Polyarteritis Nodosa
- •Allergic Granulomatous Angiitis (Churg–Strauss Syndrome)
- •Granulomatosis with Polyangiitis (Wegener)
- •Connective Tissue Diseases
- •Clinicopathological Correlates in Infectious Scleritis
- •Systemic Infections
- •Local Infections
- •5.3 Biopsy
- •5.3.1 Noninfectious Necrotizing Scleritis
- •5.3.2 Noninfectious Recurrent Diffuse or Nodular (Nonnecrotizing) Scleritis
- •5.3.3 Infectious Scleritis (Diffuse, Nodular, or Necrotizing Scleritis)
- •5.3.4 Biopsy Technique
- •5.4 Summary
- •References
- •6: Noninfectious Scleritis
- •6.1.1 Adult Rheumatoid Arthritis
- •6.1.1.1 Epidemiology
- •Signs and Symptoms of Joint Involvement
- •Extraarticular Systemic Manifestations
- •6.1.1.2 Systemic Manifestations
- •Onset
- •Tegument
- •Vessels
- •Lung
- •Heart
- •Nervous System
- •Lymph Nodes
- •Larynx
- •Felty’s Syndrome
- •Amyloidosis
- •Miscellaneous
- •6.1.1.3 Ocular Manifestations
- •Keratoconjunctivitis Sicca
- •Scleritis
- •Keratitis
- •Anterior Uveitis
- •Glaucoma
- •Cataract
- •Retinal, Choroidal, and Optic Nerve Changes
- •Motility Disturbances
- •Episcleritis
- •6.1.1.4 Laboratory Findings
- •Rheumatoid Factor
- •Antibodies to Cyclic Citrullinated Polypeptides
- •Complete Blood Count
- •Acute-Phase Reactants
- •Synovial Fluid Analysis
- •Circulating Immune Complexes
- •Antinuclear Antibodies
- •Complement
- •Cryoglobulins
- •Radiographic Evaluation
- •Diagnosis
- •6.1.2 Systemic Lupus Erythematosus
- •6.1.2.1 Epidemiology
- •6.1.2.2 Systemic Manifestations
- •Musculoskeletal
- •Tegument
- •Vessels
- •Kidney
- •Hearth
- •Nervous System
- •Lung
- •Miscellaneous
- •6.1.2.3 Ocular Involvement
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.2.4 Laboratory Findings
- •6.1.2.5 Diagnosis
- •6.1.3 Ankylosing Spondylitis
- •6.1.3.1 Epidemiology
- •6.1.3.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.3.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •6.1.3.5 Diagnosis
- •6.1.4 Reactive Arthritis (Reiter)
- •6.1.4.1 Epidemiology
- •6.1.4.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.4.3 Ocular Manifestations
- •Conjunctivitis
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.4.4 Laboratory and Radiographic Findings
- •6.1.4.5 Diagnosis
- •6.1.5 Psoriatic Arthritis
- •6.1.5.1 Epidemiology
- •6.1.5.2 Systemic Manifestations
- •Skin and Articular Involvement
- •6.1.5.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.5.4 Laboratory and Radiographic Findings
- •6.1.5.5 Diagnosis
- •6.1.6.1 Epidemiology
- •6.1.6.2 Systemic Manifestations
- •Gastrointestinal and Articular Manifestations
- •6.1.6.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Keratitis
- •6.1.6.4 Laboratory and Joint Radiologic Findings
- •6.1.6.5 Diagnosis
- •6.1.7 Relapsing Polychondritis
- •6.1.7.1 Epidemiology
- •6.1.7.2 Systemic Manifestations
- •6.1.7.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.7.4 Laboratory Findings
- •6.1.7.5 Diagnosis
- •6.1.8 Polyarteritis Nodosa
- •6.1.8.1 Epidemiology
- •6.1.8.2 Systemic Manifestations
- •6.1.8.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.8.4 Laboratory and Angiographic Findings
- •6.1.8.5 Diagnosis
- •6.1.9.1 Epidemiology
- •6.1.9.2 Systemic Manifestations
- •6.1.9.3 Ocular Manifestations
- •6.1.9.4 Laboratory Findings
- •6.1.9.5 Diagnosis
- •6.1.10 Granulomatosis with Polyangiitis (Wegener)
- •6.1.10.1 Epidemiology
- •6.1.10.2 Clinical Manifestations
- •6.1.10.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.10.4 Laboratory Findings
- •6.1.10.5 Diagnosis
- •6.1.11 Adamantiades–Behçet’s Disease
- •6.1.11.1 Epidemiology
- •6.1.11.2 Systemic Manifestations
- •6.1.11.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.11.4 Laboratory Findings
- •6.1.11.5 Diagnosis
- •6.1.12 Giant-Cell Arteritis
- •6.1.12.1 Epidemiology
- •6.1.12.2 Systemic Manifestations
- •6.1.12.3 Ocular Manifestations
- •Scleritis
- •6.1.12.4 Laboratory Findings
- •6.1.12.5 Diagnosis
- •6.1.13 Cogan’s Syndrome
- •6.1.13.1 Clinical Manifestations
- •Scleritis
- •Episcleritis
- •6.1.13.2 Laboratory Findings
- •6.2.1 Rosacea
- •6.3.1 Gout
- •6.5 Chemical Injury-Associated Scleritis
- •6.6 Summary
- •References
- •7: Infectious Scleritis
- •7.1 Bacterial Scleritis
- •7.1.1.1 Pathogenesis
- •7.1.1.2 Organisms
- •7.1.1.3 Management
- •7.1.1.4 Therapy
- •7.1.1.5 Prognosis
- •7.1.1.6 Our Experience
- •7.1.2 Mycobacterial Scleritis
- •7.1.2.1 Atypical Mycobacterial Disease
- •7.1.2.2 Tuberculosis
- •7.1.2.3 Leprosy
- •7.1.3 Spirochetal Scleritis
- •7.1.3.1 Syphilis
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •Therapy
- •7.1.3.2 Lyme Disease
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •7.1.3.3 Treatment
- •7.1.4 Chlamydial Scleritis
- •7.1.5 Actinomycetic Scleritis
- •7.1.5.1 Nocardiosis
- •7.2 Fungal Scleritis
- •7.2.1 Filamentous and Dimorphic Fungal Scleritis
- •7.2.1.1 Pathogenesis
- •7.2.1.2 Organisms
- •7.2.1.3 Management
- •7.2.1.4 Therapy
- •7.2.1.5 Our Experience
- •7.3 Viral Scleritis
- •7.3.1 Herpes Scleritis
- •7.3.1.1 Herpes Zoster Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Treatment
- •7.3.1.2 Herpes Simplex Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Therapy
- •Our Experience
- •7.3.2 Mumps Scleritis
- •7.4 Parasitic Scleritis
- •7.4.1 Protozoal Scleritis
- •7.4.1.1 Acanthamoeba
- •7.4.1.2 Toxoplasmosis
- •7.4.2 Helminthic Scleritis
- •7.4.2.1 Toxocariasis
- •7.5 Summary
- •References
- •8.1 Scleral Deposits
- •8.1.1 Scleral Protein Deposition
- •8.1.1.1 Porphyria
- •8.1.1.2 Cystinosis
- •8.1.1.3 Alkaptonuria
- •8.1.1.4 Amyloidosis
- •8.1.2 Scleral Lipid Deposition
- •8.1.2.1 Familial Hypercholesterolemia and Histiocytosis X
- •8.1.2.2 Age-Related Degeneration
- •8.1.3 Scleral Carbohydrate Deposition
- •8.1.3.1 Mucopolysaccharidosis
- •8.1.4 Scleral Mineral Deposition: Calcium
- •8.1.4.1 Hyperparathyroidism
- •8.1.4.2 Other Causes of Hypercalcemia
- •8.1.4.3 Age-Related Degeneration
- •Senile Scleral Hyaline Plaques
- •8.1.5 Scleral Pigment Deposition: Bilirubin
- •8.1.5.1 Jaundice
- •8.2 Scleral Thinning (Blue Sclerae)
- •8.2.1 Scleral Thinning in Inherited or Congenital Diseases
- •8.2.1.1 Marfan’s Syndrome
- •8.2.1.2 Osteogenesis Imperfecta
- •8.2.1.3 Pseudoxanthoma Elasticum
- •8.2.1.4 Ehlers–Danlos Syndrome
- •8.2.1.5 Keratoconus
- •8.2.1.6 Buphthalmos
- •8.2.1.7 Coloboma
- •8.2.1.8 Myopia
- •8.2.2 Scleral Thinning in Acquired Diseases
- •8.2.2.2 Paralimbal Scleromalacia
- •8.3 Scleral Thickening
- •8.3.1 Nanophthalmos
- •8.3.2 Scleropachynsis
- •8.3.3 Phthisis Bulbi
- •8.4 Scleral Tumors
- •8.4.1 Dermoid Choristomas
- •8.4.2 Epithelial Tumors
- •8.4.2.1 Papillomas or Intraepithelial Epitheliomas
- •8.4.2.2 Squamous Cell Carcinoma
- •8.4.3 Dense Connective Tissue Tumors
- •8.4.3.1 Nodular Fasciitis
- •8.4.3.2 Fibroma
- •8.4.3.3 Fibrous Histiocytoma
- •8.4.3.4 Sarcomas
- •8.4.4 Vascular Tumors
- •8.4.4.1 Hemangiomas
- •8.4.4.2 Lymphangiomas
- •8.4.5 Blood Cell Tumors
- •8.4.5.1 Leukemia
- •8.4.5.2 Lymphoma and Lymphosarcoma
- •8.4.6 Nervous Tumors
- •8.4.6.2 Neurilemmoma (Schwannoma)
- •8.4.7 Pigmented Tumors
- •8.4.7.1 Nevus
- •8.4.7.2 Melanocytoma
- •8.4.8 Secondary Tumors
- •8.5 Summary
- •References
- •9.1 Treatment of Episcleritis
- •9.2 Treatment of Scleritis
- •9.2.1 Medical Treatment
- •9.2.1.1 Rheumatoid Arthritis
- •9.2.1.2 Systemic Lupus Erythematosus
- •9.2.1.3 Polyarteritis Nodosa
- •9.2.1.4 Granulomatosis with Polyangiitis (Wegener)
- •9.2.1.5 Relapsing Polychondritis
- •9.2.1.7 Posterior Scleritis
- •9.2.1.8 Infectious Scleritis
- •9.2.2 Ancillary Therapy
- •9.2.3 Drug Management Responsibility
- •9.2.4 Surgical Treatment
- •9.3 Summary
- •References
- •Index
3.2 Diagnostic Tests |
79 |
|
|
for virus does not indicate whether a viral infection took place recently or not.
The ELISA test is the blood test most commonly used for the diagnosis of toxoplasmosis and toxocariasis. The presence of a high IgM anti-Toxoplasma and anti-Toxocara titers indicates a recent infection.
3.2.1.9 Interferon-Gamma Release Assays (IGRAs)
Recently, two in vitro assays that measure T-cell release of interferon-gamma (IFN-g) in response to stimulation with the highly tuberculosis-spe- ciÞc antigens, ESAT-6 and CFP-10, have become commercially available [74]. QuantiFERON-TB Gold¨ (Cellestis Ltd., Carnegie, Australia) is a whole-blood ELISA for measurement of IFN-g, and T-SPOT.TB¨ (Oxford Immunotec, Oxford, UK) is an enzyme-linked immunospot (ELISpot) assay. IGRAs are more speciÞc than the intracutaneous tuberculin puriÞed protein derivative (PPD) as a result of less cross-reactivity due to BCG vaccination and sensitization by nontuberculous mycobacteria [75]. IGRAs also appear to be at least as sensitive as the PPD for active tuberculosis (used as a surrogate for latent
Mycobacterium tuberculosis infection). Although diagnostic sensitivity for latent infection cannot be directly estimated because of the absence of a gold standard, these tests have shown better correlation than the PPD with exposure to M. tuberculosis in contact investigations in low-incidence settings.
Other potential advantages of IGRAs include logistical convenience, need for fewer patient visits to complete testing, avoidance of unreliable and somewhat subjective measurements such as skin induration, and the ability to perform serial testing without inducing the boosting phenomenon (a spurious PPD conversion due to boosting of reactivity on subsequent PPDs among BCGvaccinated persons and those infected with other mycobacteria). Because of the high speciÞcity and other potential advantages, IGRAs are likely to replace the PPD for latent infection diagnosis in low-incidence, high-income settings, where cross-reactivity due to BCG might adversely
impact the interpretation and utility of the PPD. Direct comparative studies in routine practice thus far suggest that the ELISpot has a lower rate of indeterminate results and probably a higher degree of diagnostic sensitivity than the wholeblood ELISA. Further studies are under way to assess the performance of these tests in contact investigations and in persons with suspected tuberculosis disease, health care workers, HIVinfected individuals, persons with iatrogenic immunosuppression, and children. These tests may be useful for antituberculous treatment decision making in chronic ocular diseases [76Ð78].
3.2.2Anterior Chamber Polymerase Chain Reaction Testing
Polymerase chain reaction (PCR) of aqueous samples obtained by anterior chamber tap (approximately 100Ð200 ml volume) can be useful in patients with sclerouveitis for detection of DNA from herpes simplex virus, VZV, cytomegalovirus, and for the parasite Toxoplasma gondii. This procedure can be performed conveniently in the outpatient setting and has been shown to be safe in the hands of an experienced ophthalmologist dealing with uveitis [79].
3.2.3Smears and Cultures
Scrapings for smears and cultures must be obtained in cases of infectious suspect. Material from vigorous scraping of the infected scleral or corneoscleral area with a surgical blade should be smeared onto glass slides for staining (Gram and Giemsa) and onto agar plates or broths for bacterial or fungal cultures (two blood agar preparations: one kept at 35¡C for blood agar, chocolate agar, Sabouraud dextrose agar, thioglycollate broth, and brainÐheart infusion medium and the other kept at room temperature). In case of acanthamoeba suspect, staining with calcoßuor white stain or Gomori methenamine silver and culture in non-nutrient agar with Escherichia coli must be performed.
80 3 Diagnostic Approach of Episcleritis and Scleritis
3.2.4 |
Skin Testing |
3.2.5 |
Radiologic Studies |
|
The PPD is a reliable method for recognizing |
All techniques of X-ray imaging rely on two |
|||
prior mycobacterial infection unless the patient |
basic properties of tissues to produce their |
|||
was vaccinated with BCG previously. The usual |
images: the ability to absorb X-ray photons and |
|||
tuberculin test is of intermediate-strength PPD |
the ability to scatter them. |
|||
(Þve tuberculin units) and is applied in the fore- |
1. Chest X-rays are of diagnostic signiÞcance in |
|||
arm. Reactions should be read by measuring the |
tuberculosis, granulomatosis with polyangiitis |
|||
transverse diameter of induration as detected by |
(Wegener), allergic granulomatous angiitis |
|||
gentle palpation at 48Ð72 h [80]. Patients with |
(ChurgÐStrauss syndrome), and atopy. |
|||
tuberculosis have |
reactions with a mean of |
2. Sinus Þlms showing mucosal thickening and/ |
||
17 mm; patients infected but with no active dis- |
or destruction of bony walls can be helpful in |
|||
ease have similar reactions. Therefore, a positive |
the diagnosis of granulomatosis with poly- |
|||
test means a prior mycobacterial infection and |
angiitis (Wegener). |
|||
does not rule out other etiologic factors, as it may |
3. Sacroiliac X-rays are of diagnostic signiÞ- |
|||
be a coincidental Þnding. Repeated skin testing |
cance in ankylosing spondylitis, reactive |
|||
with PPD does not lead to positive reactions in |
arthritis, psoriatic arthritis, and arthritis asso- |
|||
uninfected persons. |
ciated with inßammatory bowel disease. |
|||
Every individual is normally exposed and |
4. Limb joint X-rays, such as hand, wrist, foot, |
|||
sensitized to many antigens. Modern prophylac- |
and knee joint X-rays, can show the arthritic |
|||
tic immunization results in the purposeful expo- |
changes characteristic of rheumatoid arthritis, |
|||
sure to antigens from microorganisms responsible |
juvenile rheumatoid arthritis, gout, psoriatic |
|||
for diphtheria, tetanus, mumps, inßuenza, and |
arthritis, and arthritis associated with inßam- |
|||
other virus infections. In addition, natural expo- |
matory bowel disease. |
|||
sure results in sensitization to antigens prepared |
|
|
||
from streptococci, staphylococci, certain com- |
|
|
||
mon fungi, and other ubiquitous antigens. Skin |
3.2.6 |
Anterior Segment Fluorescein |
||
tests elicit delayed cutaneous hypersensitivity |
|
Angiography |
||
reactions to these antigens in most healthy sub- |
|
|
||
jects. Impairment of delayed hypersensitivity |
The information that can be obtained from ante- |
|||
reaction to an antigen in an adequately exposed |
rior segment ßuorescein angiography may be a |
|||
subject is called anergy. Anergy or hyporeactiv- |
valuable adjunct to the diagnosis of scleritis. For |
|||
ity to skin testing is typical, although not diag- |
example, although most forms of anterior scleral |
|||
nostic of lepromatous leprosy, herpes zoster, or |
disease can be diagnosed clinically, difÞculties |
|||
sarcoidosis. Systemic steroid therapy may |
sometimes arise in distinguishing between severe |
|||
reverse |
anergy, |
whereas immunosuppressive |
episcleritis and diffuse anterior scleritis or |
|
therapy, such as cyclosporin, may suppress a |
between the relatively benign diffuse or nodular |
|||
positive skin test. |
|
anterior scleritis and the early changes of the |
||
Skin testing can also help detect allergies, |
more severe necrotizing scleritis. Early detection |
|||
such as pollen, animal dander, mold, dust, and |
of the most severe forms of scleritis is crucial if |
|||
many other environmental allergens. Direct |
one is to institute correct treatment before more |
|||
reproduction of an immediate allergic reaction by |
destructive changes occur. Because the adequate |
|||
introducing a small amount of extract of sus- |
therapy of scleritis depends on an accurate diag- |
|||
pected allergen into the skin is a good method |
nosis, it is important to Þnd objective methods to |
|||
with which to diagnose atopy. Two procedures, |
evaluate the different clinical conditions. Anterior |
|||
the intradermal test and the prick test, are the |
segment ßuorescein angiography has been found |
|||
most consistent and interpretable. |
to show |
characteristic patterns in the various |
||
3.2 Diagnostic Tests |
81 |
|
|
forms of episcleritis and scleritis, providing considerable information in guiding subsequent therapy [81, 82].
In our experience, corneal involvement can be found in 13% of patients with scleritis. Although most of the different forms of keratitis associated with scleral disease can be diagnosed clinically, differentiation between the early changes of the relatively benign peripheral corneal opaciÞcation with or without neovascularization and the early changes of the more serious corneal thinning, either with limbal guttering or peripheral corneal ulceration, can sometimes be difÞcult. Early detection of the most severe forms of keratitis associated with scleritis is important if one is to institute adequate treatment before visual acuity becomes affected. Because the accurate diagnosis of keratitis associated with scleritis can add valuable information to the choice of therapy, it is important to Þnd objective methods to evaluate early keratitis. Anterior segment ßuorescein angiography can sometimes help in this regard [83].
Adequate medical treatment for scleral inßammation with or without corneal involvement frequently results in halting the process, either through new vessel formation to cover the defect or through recanalization of existing vessels [84]. Although most of the individual responses to treatment can be easily monitored by clinical examination, difÞculties sometimes arise in being certain if the scleral disease with or without corneal involvement is completely under control. Anterior segment ßuorescein angiography can sometimes be of assistance in monitoring the effect of medical therapy [85].
If in spite of intensive medical therapy no new vessels are formed or no preexisting vessels are recanalized, progressive thinning of the sclera and/or cornea with possible eventual perforation may occur. In these cases, tectonic surgery, such as scleral, corneal, or sclerocorneal grafting, must be considered to maintain the integrity of the eye [86]. Although the site and extent of the surgical procedure can be frequently decided by clinical examination, determination of the amount of necrotic tissue to be removed and replaced surgically can sometimes be difÞcult. Anterior seg-
ment ßuorescein angiography can sometimes be useful in deciding the extent of appropriate surgical intervention [85].
3.2.6.1 Anterior Segment Fluorescein Angiography Techniques
Conventional photographic ßuorescein angiography [81, 87Ð93], low-dose photographic ßuorescein angiography [94], low-dose ßuorescein videoangiography [95], and scanning angiographic microscopic ßuorescein videoangiography [96] are different techniques used to describe the circulatory dynamics of the anterior segment of the eye, such as the direction of ßow, distinction between arteries and veins, and integrity of the circulation.
Fluorescein angiography has been available for examining the retinal microcirculation since 1961 [97], when venous injection of low-molec- ular-weight sodium ßuorescein was used to demonstrate abnormalities in the retinal capillaries, retinal pigment epithelial cells, and BruchÕs membrane. The tight apposition of contiguous retinal capillary endothelial cells may explain, at least in part, why normal retinal vessels do not leak ßuorescein [88, 98]. Iris capillary endothelial cells also are joined by tight junctions, and anterior segment ßuorescein angiography was introduced in 1968 [99, 100] with the primary purpose of diagnosing iris lesions. Conventional anterior segment ßuorescein angiography has not, however, been widely used for conjunctival and scleral abnormalities because normal conjunctival and episcleral vessels leak molecules smaller than serum albumin, such as ßuorescein. Low-molecular-weight molecules may escape from the conjunctival and episcleral vessel lumens by crossing the interendothelial clefts, endothelial cells through pinocytotic vesicles, or both [101]. Interestingly, the limbal vessels never leak ßuorescein, suggesting that their endothelial cells are united by tight junctions [102]. Five milliliters of 10% sodium ßuorescein via antecubital vein injection rapidly extravasates from conjunctival and episcleral vessels, restricting the diagnostic value of this technique to the demonstration of either early leakage or gross hypoperfusion [81]. If leakage is to be avoided, the ßuorescein
